Loading…
Results presented in a late-breaking oral presentation at IDWeek 2025.
Armata Pharmaceuticals, Inc. (ARMP) announced positive results from a Phase 2a study of its Staphylococcus aureus bacteriophage cocktail, AP-SA02, as part of the diSArm study. The findings were shared in a late-breaking oral presentation at IDWeek 2025.
The study demonstrated the safety and efficacy of AP-SA02 in treating Staphylococcus aureus infections. Detailed data from the presentation highlighted significant reductions in bacterial load and improvements in patient outcomes.
As of the latest available data, Armata Pharmaceuticals has a free float of 10,974,500 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.